A Phase II Study of Oxaliplatin and Capecitabine in Patients With Measurable Metastatic Adenocarcinoma of the Esophagus, Gastroesophageal Junction, and Gastric Cardia

Inclusion Criteria

DISEASE CHARACTERISTICS:

- Histologically or cytologically confirmed adenocarcinoma of the esophagus,
gastroesophageal junction, or gastric cardia for which no potentially curative or
significant palliative therapy exists

- Unresectable disease

- Gastric cardia is defined as no more than 5 cm from the gastroesophageal
junction into the stomach

- Measurable disease

- No known CNS metastases

PATIENT CHARACTERISTICS:

Age:

- 18 and over

Performance status:

- ECOG 0-2

Life expectancy:

- At least 12 weeks

Hematopoietic:

- Absolute neutrophil count at least 1,500/mm^3

- Platelet count at least 100,000/mm^3

Hepatic:

- Bilirubin no greater than upper limit of normal (ULN)

- AST no greater than 3 times ULN

- Alkaline phosphatase no greater than 2 times ULN

Renal:

- Creatinine no greater than 1.5 times ULN

- Creatinine clearance at least 60 mL/min

Cardiovascular:

- No New York Heart Association class III or IV heart disease

Other:

- Able to swallow capecitabine

- No unresolved gastrointestinal bleeding

- No uncontrolled infection

- No chronic debilitating disease

- No peripheral neuropathy grade 2 or greater

- No other malignancy within the past 5 years except adequately treated basal cell or
squamous cell skin cancer or adequately treated noninvasive carcinoma

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy:

- No prior immunotherapy or biological therapy for recurrent or metastatic disease

- No concurrent biologic agents

Chemotherapy:

- No prior chemotherapy for recurrent or metastatic disease

- Prior adjuvant or neoadjuvant chemotherapy (including combination chemotherapy and
radiotherapy) allowed

- No other concurrent chemotherapy

Endocrine therapy:

- Not specified

Radiotherapy:

- See Chemotherapy

- No prior radiotherapy for recurrent or metastatic disease

- No prior radiotherapy to more than 25% of the bone marrow

- Prior adjuvant or neoadjuvant radiotherapy allowed

- More than 4 weeks since prior radiotherapy

- No concurrent radiotherapy

Surgery:

- More than 4 weeks since prior abdominal exploration with surgical resection

- More than 3 weeks since prior abdominal exploration without surgical resection

Other:

- No concurrent oral cryotherapy during oxaliplatin administration